MAPT and tauopathy: Relevantly, a comprehensive mass spectrometry (MS)-based screening carried out on CSF samples from patients affected from AD and other tauopathies has confirmed that the first NH2 26-44 aminoacids of human tau are epitopes potentially targetable for promising immunotherapeutic interventions, being largely represented into proteomic profile of diseased secreted proteins [21].